The Journal of Medicinal Chemistry recently publishes an article titled, “Discovery of Clinical Candidate PF-06648671: A Potent γ-Secretase Modulator for the Treatment of Alzheimer’s Disease”. Amyloid β-peptide (Aβ) accumulation is one of the key hallmarks of Alzheimer’s disease (AD). γ-secretase cleaves the amyloid precursor protein (APP) into pathologically relevant Aβs, and has been widely studied as a potential target for the treatment of AD.
Pfizer‘s PF-06648671 is a Gamma secretase modulator (GSM) targeting APP processing. It is found to have excellent central exposure in human and robust reduction of amyloidogenic forms (Aβ42) in cerebrospinal fluid (CSF).